Cargando…

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell lymphoproliferative malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). ATL is an orphan disease with no curative drug treatment regimens urgently needing new combination therapy. HTLV-1-infected cells rely on viral proteins,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daenthanasanmak, Anusara, Bamford, Richard N., Yoshioka, Makoto, Yang, Shyh-Ming, Homan, Philip, Karim, Baktiar, Bryant, Bonita R., Petrus, Michael N., Thomas, Craig J., Green, Patrick L., Miljkovic, Milos D., Conlon, Kevin C., Waldmann, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006306/ https://www.ncbi.nlm.nih.gov/pubmed/35030628 http://dx.doi.org/10.1182/bloodadvances.2021005948

Ejemplares similares

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
por: Oien, Derek B., et al.
Publicado: (2023)

Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL
por: Miljkovic, Milos D., et al.
Publicado: (2021)

Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia
por: Daenthanasanmak, Anusara, et al.
Publicado: (2020)

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL
por: Kurahashi, Yuki, et al.
Publicado: (2022)

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
por: Bowers, Jackson T., et al.
Publicado: (2023)

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
por: Bruscaggin, Alessio, et al.
Publicado: (2021)

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge
por: Tadmor, Tamar, et al.
Publicado: (2023)

Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing
por: Migita, Natacha Azussa, et al.
Publicado: (2023)

Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
por: Ollila, Thomas A., et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023)

FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells
por: Yang, Scarlett Y., et al.
Publicado: (2022)

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia
por: Sexauer, Amy N., et al.
Publicado: (2023)

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
por: Bewicke-Copley, Findlay, et al.
Publicado: (2022)

NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia
por: Yoshida, Masanori, et al.
Publicado: (2021)

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma
por: Vanden Bempt, Marlies, et al.
Publicado: (2022)

Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
por: Lynggaard, Line Stensig, et al.
Publicado: (2022)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels
por: Au, Amanda E., et al.
Publicado: (2022)

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
por: Barilà, Gregorio, et al.
Publicado: (2023)

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
por: Aubrais, Raphaelle, et al.
Publicado: (2022)

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
por: Imber, Brandon S., et al.
Publicado: (2021)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway
por: Butler, Miriam, et al.
Publicado: (2021)

Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
por: Ren, Jingjing, et al.
Publicado: (2022)

Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL
por: Passet, Marie, et al.
Publicado: (2022)

Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia
por: Leongamornlert, Daniel, et al.
Publicado: (2023)

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
por: Brink, Mirian, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
por: Tran, Thai Hoa, et al.
Publicado: (2022)

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL
por: Largeot, Anne, et al.
Publicado: (2023)

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
por: Koh, Min Jung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_77d3cvuo26k0p7hvdjdmk7mg43